Zhejiang Tongwu Biopharmaceutical

Tongwu Biopharmaceutical is a clinical-stage biotechnology company based in Zhejiang, China, specializing in the discovery and development of next-generation cancer immunotherapies. The company focuses on developing innovative biologics, particularly monoclonal and bispecific antibodies targeting novel immune checkpoints such as VISTA and CD47. Their lead programs are designed to overcome the limitations of current PD-1/PD-L1 therapies by addressing immune evasion in the tumor microenvironment. Tongwu Biopharmaceutical leverages a proprietary antibody discovery platform to advance a robust pipeline of candidates for both solid tumors and hematological malignancies.